



Vaccine

journal homepage: www.elsevier.com/locate/vaccine

Natural history and epidemiology of respiratory syncytial virus infection in the Middle East: Hospital surveillance for children under age two in Jordan



Natasha Halasa^{a,c,**}, John Williams^f, Samir Faouri^d, Asem Shehabi^e, Sten H. Vermund^{a,c}, Li Wang^b, Christopher Fonnesbeck^b, Najwa Khuri-Bulos^{e,*}

^a Departments of Pediatrics, Vanderbilt University, Nashville, TN, USA

^b Department of Biostatistics, Vanderbilt University, Nashville, TN, USA

^c Institute for Global Health, Vanderbilt University, Nashville, TN, USA

^d Department of Pediatrics, Al Bashir Hospital, Amman, Jordan

^e Department of Pathology-Microbiology at University of Jordan, Amman, Jordan

^f Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA

ARTICLE INFO

Article history:

Available online 24 August 2015

Keywords:

Respiratory syncytial virus
Acute respiratory tract infection
Jordan
Middle East
Child
Infant
Surveillance

ABSTRACT

Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and viral pneumonia in infants and young children worldwide. In the Middle East and Arab countries, the burden of RSV-associated hospitalizations is not well characterized. We sought to determine the burden and clinical/epidemiological characteristics of RSV hospitalization in young children in Amman, Jordan. We investigated risk factors for severity including vitamin D levels.

Methods: We conducted viral surveillance with clinical and demographic data in children <2 years admitted with respiratory symptoms and/or fever at the Al-Bashir Government Hospital from March 16, 2010 to March 31, 2013. Nasal/throat swabs were obtained and placed into lysis buffer, and frozen at -80°C until testing by real-time RT-PCR for 11 respiratory viruses. Heel stick blood or sera samples for 25-hydroxyvitamin D [25(OH)D] levels were obtained and sent to a central laboratory for mass spectrometry. **Results:** Of the 3168 children, >80% testing positive for one virus, with RSV the most common virus detected (44%). The RSV-associated hospitalization rate was highest in children <6 months with an annual range of 21.1–25.9 per 1000, compared to 6.0–8.0 in 6–11-month-olds and 1.6–2.5 in 12–23-month-olds. RSV-positive children compared with RSV-negative were more likely to be previously healthy without underlying medical conditions, less likely to be born prematurely, had a higher frequency of supplemental oxygen use, and had lower median vitamin D levels. Risk factors for oxygen use in RSV-positive children included underlying medical conditions, lack of breastfeeding, younger age, and higher viral load.

Conclusion: RSV is a major cause of illness in hospitalized Jordanian children and is associated with increased severity compared to other respiratory viruses. Children with RSV in the Middle East would benefit from future RSV vaccines and antiviral therapy.

© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and viral pneumonia in infants and young children worldwide [1]. A global incidence estimate for RSV-associated acute respiratory infections (ARI) in children <5 years in 2005 suggests 33.8 million new episodes of RSV-associated ARI with at least 3.4 million episodes necessitating hospital admission [2]. An estimated 66,000–190,000 children died from RSV-associated ARI, and 99% of these deaths occurred in developing countries, though the Middle East was not considered due to paucity of published data [2].

* Corresponding author. Tel.: +962 65353444; fax: +962 65353388.

** Corresponding author at: Vanderbilt University, Division of Pediatric Infectious Diseases, 1161 21st Ave South D7232, MCN, Nashville, TN 37232, USA. Tel.: +1 615 343 6738; fax: +1 615 343 9723.

E-mail addresses: natasha.halasa@vanderbilt.edu (N. Halasa), jvw@chp.edu (J. Williams), samirf1952@yahoo.com (S. Faouri), ashehabi@go.com.jo (A. Shehabi), sten.vermund@vanderbilt.edu (S.H. Vermund), li.wang@vanderbilt.edu (L. Wang), christopher.fonnesbeck@vanderbilt.edu (C. Fonnesbeck), Najwa.Khuri@gmail.com, nkhuri@ju.edu.jo (N. Khuri-Bulos).

Specifically, very few population-based viral surveillance studies, including determining burden of RSV disease, have been performed in the Middle East, and few of these have used highly sensitive molecular techniques such as real-time reverse-transcriptase polymerase chain reaction [3–13]. Also, many of these studies had small samples sizes and the duration of the study period was usually for only one respiratory season. Thus, the true prevalence and burden of RSV disease in the Middle East remains unknown.

Recognizing that the viral etiology of ARI among Middle Eastern children in Arab countries was poorly characterized, in 2007 we had conducted a pilot viral surveillance study in children <5 years admitted with respiratory symptoms and/or fever at two hospitals in Amman, Jordan over a three-month winter period [14–16]. Of the 728 subjects enrolled, >80% tested positive for a virus by RT-PCR, with 64% testing positive for RSV. Compared to RSV-negative subjects, the RSV-positive subjects had lower median age, higher rates of oxygen use, longer hospital stay, and higher hospital charges. These pilot data suggested that in young hospitalized Jordanian children, the medical and financial burden of RSV was high. To more definitively address the burden of RSV disease in the present study, we conducted a three-year viral surveillance in Amman, Jordan and limited the age group to children <2 years, the age group representing >90% of the cases in our 2007 pilot study.

2. Methods

2.1. Study design

We conducted a prospective, year-round viral surveillance study enrolling children <2 years with respiratory symptoms and/or fever within 48 h of hospital admission at Al-Bashir Hospital, the major government-run referral center in Amman, Jordan. Children were enrolled five days a week (Sunday through Thursday) if they presented with a history of fever and/or respiratory symptoms and one of the following admission diagnoses: ARI, apnea, asthma exacerbation, bronchiolitis, bronchopneumonia, croup, cystic fibrosis exacerbation, febrile seizure, fever without localizing signs, respiratory distress, pneumonia, pneumonitis, pertussis, pertussis-like cough, rule out sepsis, upper respiratory infection (URI), or other. Children were excluded only if they had chemotherapy-associated neutropenia and/or were newborns who had never been discharged.

Written informed consent was obtained from parents or guardians before enrollment into the study. The institutional review boards at the University of Jordan, the Jordanian Ministry of Health, and Vanderbilt University approved the study.

2.2. Study location

Al-Bashir Hospital is one of three major government-run referral medical centers that serve the population of Amman, which is estimated to be >2 million. With its 185 pediatric beds (120 pediatric and 65 neonatal intensive care unit), the Ministry of Health estimates that during the study period, the Al-Bashir Hospital provided care for at least 50–60% of children in Amman (author SF, personal communication). Al-Bashir provides care to government employees and their dependents, underprivileged families in Amman, and patients who are referred from other health care centers in Jordan [17]. It is located in the low-income and densely populated Al-Ashrafieh area of eastern Amman, which includes the nearby Al Wihdat Palestinian refugee camp. Patients with financial constraints are also admitted to this hospital since Jordan adopted a policy of providing no-cost medical care to children <6 years at government-run institutions regardless of insurance status. During the 3-year study period, there were 17,557 hospitalizations

admitted to the pediatric wards, 11,230 (64%) among children <2 years.

2.3. Data and specimen collection

Trained research staff obtained nasal and throat swabs from all enrolled children. If permission was granted, staff also obtained blood by a heel stick or venipuncture. Demographic characteristics and medical and social histories were obtained using standardized questionnaires; parents were queried in Arabic and the information was recorded in English. The medical charts were abstracted after discharge; demographic, epidemiologic, and clinical data were collected systematically. Vital signs at admission were recorded by clinicians. Oxygen saturations were collected as ranges: 95–100%, 90–94%, 85–89%, and <85%. Flaring or retractions were categorized as none, mild (flaring only), moderate (retractions), or severe (accessory muscle use). Wheezing on physical exam was categorized as none, end-expiratory, full expiratory or inspiratory, full expiratory and inspiratory, or not specified. Cyanosis was recorded as none, circumoral on crying only, circumoral at rest, generalized cyanosis at rest, or not specified. Documentation of microbiological data was obtained and viral identification laboratory results were recorded. Intensive care unit (ICU) stays included children who were either admitted directly to the ICU or were transferred in during the admission. Smoke exposure included both cigarette and/or nargalia (hookah pipe) exposure. Underlying conditions were collected and were categorized as the following: diabetes, heart disease, down's syndrome, kidney disease, sickle cell, cystic fibrosis, cancer, genetic/metabolic, cerebral palsy, neurological, mental retardation/developmental delay, seizure disorder, chronic diarrhea (e.g. >2 weeks), gastroesophageal reflux disease, immunodeficiency, asthma/reactive airway disease, and liver disease. We entered data into a standardized, secured REDCap™ (Research Electronic Data Capture, Vanderbilt University, Nashville, TN, USA) database system [18]. Data quality checks were performed on at least 10% of the charts and all case report forms were verified after entry.

2.4. Classification

To better understand the role of RSV in pediatric lower respiratory tract infection (LRTI), we identified a sub-cohort of children. The LRTI cohort consisted of children with an admission diagnosis of asthma, bronchiolitis, bronchopneumonia, pneumonia, respiratory distress, or wheezing; or clinical signs of retractions or accessory muscle use; or wheezing on examination.

2.5. Laboratory testing

Nasal and throat swabs were collected and combined in transport medium (M4RT®, Remel, USA), aliquoted into MagMAX™ Lysis/Binding Solution Concentrate (Life Technologies, USA), snap frozen, and stored at –80 °C. Original and lysis buffer aliquots were shipped on dry ice and were tested by RT-PCR for eleven respiratory viruses (RSV, human metapneumovirus (HMPV), human rhinovirus (HRV), influenza (flu) A and B, C, and parainfluenza (PIV) virus 1, 2, and 3, adenovirus (adeno), and Middle East respiratory syndrome coronavirus (MERS-CoV) [19–25,15,26,27].

2.6. Vitamin D testing

Blood was placed directly onto filter paper and air dried for ≥30 min before storage at room temperature and kept in a dry state until shipment to ZRT Laboratory (Beaverton, OR, USA) for vitamin D assay per protocol [28,29–33].

2.7. Statistical analysis

Descriptive statistics were presented as frequency (percentage) or median and interquartile range (IQR) where appropriate. Categorical variables were compared using Pearson Chi-square test. Continuous variables were compared using Mann-Whitney U test. For ≥ 3 groups comparison of continuous variables, Kruskal–Wallis test was used. We fit a multivariable logistic model to analyze the risk of oxygen use, ICU stay, mechanical ventilation, and length of stay as indicators for severity. The risk factors assessed included breastfeeding, vitamin D level, age at enrollment, gestational age, birth weight, gender, past medical history, smoke exposure, daycare, the four most common admission diagnoses (pneumonia, bronchopneumonia, bronchiolitis, and suspected sepsis) and RSV count. Daycare was removed from the ICU model because there were not subjects who were admitted to the ICU who attended daycare. All analyses were performed using statistical software R version 3.1.2 (<http://www.R-project.org/>).

The enrolled sample was used to provide model-based estimates prevalence of RSV. The data were filtered to exclude admissions of individuals not residing in Amman. We used a Bayesian hierarchical model to derive prevalence estimates for each of the three years of the study [20]. In order to derive prevalence, estimates of the under 2-year-old Jordanian population were obtained from the World Bank online database, and the proportion of the population residing in Amman (35%) was taken from the 2012 national census [21]. These values were used in a binomial model to estimate the population of children <2 years of age in Amman in 2010–2012. The market share for Al-Bashir hospital was modeled as a random variable, and given a uniform prior distribution between 50 and 60% of the market share. Finally, to account for the enrollment effort, the probability of enrollment was set to 71.4% (5 of 7 days) and used in a binomial model for the number enrolled in the study. Prevalence was given a diffuse beta (1,5) prior in all models. Each model was fitted using Markov chain Monte Carlo [22] methods as implemented in the PyMC 2.3 software package [23]. Models were run for 100,000 iterations, with the first 90,000 iterations conservatively discarded as burn-in. Models were checked for convergence using the Gelman–Rubin diagnostic [20] and for goodness of fit using posterior predictive checks [24].

3. Results

3.1. Study population

From March 16, 2010 to March 31, 2013, 3793 patients were eligible, of whom 3175 (83.7%) were enrolled. Seven patients (0.2%) were excluded: three were ≥ 2 years and four had the admission diagnosis of meningitis. Thus, 3168 subjects (83.5% of eligible subjects) were included in the final cohort.

3.2. Clinical and demographic characteristics of entire surveillance cohort

The median age was 3.5 months (range 0.06–23.64 months), with 31% of the children <2 month, 34% 2–5 months, 20% 6–11 months (total 85% <1 year) and 15% 12–23 months. Sixty percent were male. Nearly 90% of the children had Jordanian parents, 7% Palestinian, and 3% other. By medical chart reviews or parent histories, 11.8% of the children were noted to have an underlying medical condition and 14% of the children had a history of prematurity (<37 weeks). Prior to hospitalization, 41% received an antibiotic and nearly the entire cohort (92%) were administered an antibiotic during their hospital stay. Almost 93% of the children had one of five admission diagnoses: bronchopneumonia (32%), suspected sepsis (29%), bronchiolitis (17%), pneumonia (12%), and pertussis-like cough (7%). We had vitamin D levels for 2688 (85%) children; the median vitamin D level was 16.5 ng/mL.

3.3. Viral detection

All 3168 children had a nasopharyngeal swab obtained. A virus was detected in 81% of the children. The most common virus detected was RSV (44%), followed by HRV (39%), adeno (15%), HMPV (9%), PIV 1, 2, and 3 (6%), and Flu A, B and C (4%). MERS-CoV was not detected. Fig. 1 includes the frequency and distribution of RSV over a three-year period, with peaks in January and February. Of the 1397 RSV-positive children, 669 (48%) had at least one other virus detected and Fig. 2 illustrates the combination of these co-infections.




Fig. 1. The frequency of RSV-positive hospitalized children over the three-year study period (March 16, 2010 through March 31, 2013).




Fig. 2. The percent of RSV-positive only and RSV-positive with co-detection.

Table 1

Estimated Rates of RSV Hospitalizations with 95% credible intervals by year and by age groups per 1000 persons.

	<6 months	6–11 months	12–23 months
Year 1 (03/16/2010–3/31/2011)	21.1 (17.9, 24.4)	6.8 (5.4, 8.4)	1.6 (1.1, 2.1)
Year 2 (04/01/2011–3/31/2012)	23.5 (19.8, 26.8)	6.0 (4.7, 7.5)	2.3 (1.7, 2.9)
Year 3 (04/01/2013–3/31/2013)	25.9 (22.0, 29.4)	8.0 (6.5, 9.9)	2.5 (1.9, 3.2)

3.4. RSV hospitalization rates

Using Jordanian census data and restricting our cohort to children who resided in Amman, we were able to estimate RSV hospitalization rates for each study year (Table 1). Of the 3168 children, 3048 (96.2%) resided in Amman. The RSV rates were substantially higher in children <6 months (21.1–25.9 per 1000) compared to the older age groups: 6–8 per 1000 in 6–11-month-olds and 1.6–2.5 per 1000 in children ages 12–23 months.

3.5. Clinical and demographic characteristics comparing RSV-positive to RSV-negative children

A comparison of RSV-positive children compared to RSV-negative is shown in Table 2. RSV-positive children were more likely to have been previously healthy, with no significant underlying medical condition, and were less likely to be born prematurely (Table 2). RSV-positive subjects were also more likely to have the diagnoses of bronchiolitis, bronchopneumonia, pneumonia, and pertussis-like cough compared to RSV-negative children (Table 2). When comparing presenting symptoms as reported by parents, RSV-positive children were more likely to present with cough and shortness of breath and less likely to present with fever, decreased activity, diarrhea, or vomiting (Table 2).

The RSV-positive children were more likely to have a physician document wheezing, cyanosis, and abnormal flaring and retractions on exam and an abnormal chest radiograph (Table 2). These children had a comparatively higher frequency of supplemental oxygen use, were more likely to have <90% oxygen saturation at admission (9% vs. 6% for RSV-negative children, $p < 0.01$), and were

less likely to have oxygen saturation >95% (36% vs. 42%, $p < 0.01$). The RSV-positive children also had lower median vitamin D levels (Table 2). The mortality rate was lower in the RSV-positive children, (0.5% vs. 1%, $p = 0.015$). In order to understand if co-infection with another virus was associated with increased severity, we compared RSV-only children with RSV co-infected children. RSV-only children had slightly higher percentage of cough reported prior to admission 96% vs. 93% ($p < 0.01$), were more likely to report a runny nose/congestion (3% vs. 1%, $p = 0.01$), and had comparable severity of disease.

3.6. Clinical characteristics of children with lower respiratory tract infection

In order to characterize the features of RSV-associated LRTI, we analyzed the subset of children who presented with LRTI. Of the 3168 children, 2263 (71.4%) met criteria for LRTI. Of these, 1210 (53.5%) had RSV, 785 (34.7%) had another virus detected, and 268 (11.8%) had no virus detected (Table 3). Children with RSV were more likely to be younger, have a history of breastfeeding, have the diagnoses of bronchiolitis or pertussis-like cough, present with cough or shortness of breath, and have cyanosis on exam compared to other virus-positive and virus-negative children (Table 3). In addition, they were more likely to require oxygen and had lower median vitamin D levels (Table 3). Children who had virus-negative LRTI were more likely to have an underlying medical condition, be admitted to the ICU, and die compared to the other groups (Table 3).

3.7. Risk factors for illness severity: Oxygen use, ICU stay, mechanical ventilation, and length of stay

To assess for severity of illness indicators, we compared the following outcomes in RSV-positive children: oxygen requirement, any ICU stay, mechanical ventilation, and length of stay (Tables 4 and 5) in a univariate and/or multivariable analyses. Lack of breastfeeding, lower age, and higher viral load (indicated by lower Ct values) were associated with oxygen use, while the diagnoses of bronchiolitis, suspected sepsis, and bronchopneumonia were not associated (Table 4). The diagnoses of pneumonia and suspected sepsis and lower age were more likely to be associated with ICU stay but less likely with the diagnosis of bronchopneumonia

Table 2

Clinical and demographic comparisons of RSV-positive and RSV-negative children.

Total N = 3168	RSV-positive N = 1397	RSV-negative N = 1771	p-Value
Age (months) median	3.5 months	3.5 months	0.16
0–1 months	135 (10%)	248 (14%)	<0.01
2–5 months	736 (53%)	772 (44%)	
6–11 months	327 (23%)	394 (22%)	
12–23 months	199 (14%)	357 (20%)	
Sex (male)	834 (60%)	1078 (61%)	0.50
Daycare**	27 (2%)	23 (1%)	0.16
Breastfeeding	1200 (86%)	1461 (82%)	0.01
No past medical history	1286 (92%)	1507 (85%)	<0.01
Smoke exposure	1070 (77%)	1355 (77%)	0.96
Antibiotics prior to hospitalization	653 (47%)	633 (36%)	<0.01
Antibiotics during hospitalization ^a	1279 (92%)	1612 (92%)	0.61
Gestational Age	179 (13%)	271 (15%)	0.046
Median % < 37 weeks			
Birth weight (median, kg) ^a	3.0	3.0	0.074
Admission diagnosis			
Bronchiolitis	374 (27%)	173 (10%)	<0.01
Bronchopneumonia	476 (34%)	544 (31%)	0.045
Pneumonia	225 (16%)	169 (10%)	<0.01
Suspected sepsis	248 (18%)	664 (37%)	<0.01
Pertussis-like cough	129 (9%)	96 (5%)	<0.01
Presenting symptoms			
Fever	649 (46%)	1113 (63%)	<0.01
Cough	1320 (94%)	1046 (59%)	<0.01
Shortness of breath	1039 (74%)	793 (45%)	<0.01
Runny nose/congestion	40 (3%)	37 (2%)	0.16
Decrease appetite	301 (22%)	399 (23%)	0.51
Seizures/convulsions	19 (1%)	106 (6%)	<0.01
Decrease activity ^a	77 (20%)	238 (36%)	<0.01
Diarrhea	69 (5%)	248 (14%)	<0.01
Vomiting	186 (13%)	336 (19%)	<0.01
Key examination findings			
Wheezing	926 (66%)	831 (47%)	<0.01
Cyanosis	362 (26%)	258 (15%)	<0.01
Flaring/retractions	173 (12%)	108 (6%)	<0.01
Abnormal chest X-ray ^b	1122 (82%)	955 (60%)	<0.01
Outcomes			
O2 requirement ^c	566 (41%)	447 (25%)	<0.01
Days on oxygen (25th, 50th, 75th, mean, standard deviation) ^d	1 2 5 (3.76 ± 3.3)	1 2 4 (3.28 ± 3.1)	0.041
Mechanical ventilations ^d	52 (4%)	59 (3%)	.54
ICU stay ^e	126 (9%)	158 (9%)	0.89
Median length of stay (days) ^f	4	4	0.2
Death ^d	7 (0.5%)	24 (1%)	0.015
Vitamin D level (ng/mL) ^g	14.3 ng/mL	18.2 ng/mL	<0.01

^a 3147.^b 2961.^c 3137.^d 3136.^e 3140.^f 3139.^g 2688.^Δ 1012.^{*} n = 1044.^{**} 3167.[•] 3166.

(Table 4). Mechanical ventilation was associated with younger age and higher vitamin D level (Table 4). The following were associated with longer length of stay: having an underlying medical condition, lack of breastfeeding, the diagnoses of pneumonia and suspected sepsis, younger age, lower gestational age, and higher viral load (indicated by lower Ct values) in contrast, the diagnoses of bronchiolitis and bronchopneumonia were associated with shorter length of stay (Table 5).

4. Discussion

In our 2010–2013 surveillance window, RSV was a major cause of ARI hospitalizations in Jordanian children <2 years, with consistent annual peaks in January and February. Our study represents one of the largest cohort studies of RSV-infected hospitalized children, including within the Middle East [10–13,34–43]. RSV is well-recognized cause of ARI globally [2], but even comprehensive

Table 3

Clinical and demographic comparisons of lower respiratory tract infection by RSV-positive, other virus-positive, and virus-negative children.

Total Cohort N = 2263	RSV-positive LRTI (N = 1210)	Virus other-positive LRTI (N = 785)	Virus-negative LRTI (n = 268)	p-Value
Age (months) median	4.2	7.1	6.2	<0.01
0–1 months	78 (6%)	30 (4%)	20 (7%)	<0.01
2–5 months	618 (51%)	249 (32%)	92 (34%)	
6–11 months	320 (26%)	279 (36%)	76 (28%)	
12–23 months	194 (16%)	227 (29%)	80 (30%)	
Sex (male)	733 (61%)	484 (62%)	154 (57%)	0.48
Daycare ^a	26 (2%)	12 (2%)	7 (3%)	0.46
Breastfeeding	1031 (85%)	627 (80%)	211 (79%)	0.002
No past medical history	1104 (91%)	629 (80%)	207 (77%)	<0.01
Smoke exposure	929 (77%)	594 (76%)	213 (79%)	0.44
Antibiotics prior to hospitalization	605 (50%)	371 (47%)	128 (48%)	0.46
Antibiotics during hospitalization ^b	1099 (91%)	708 (91%)	236 (88%)	0.28
Gestational Age	148 (12%)	127 (16%)	41 (15%)	0.04
Median % < 37 weeks				
Birth weight (kg) ^c (25th, 50th, 75th, mean, standard deviation)	2.6 3.0 3.5 (3.0 ± 0.6)	2.5 3.0 3.5 (2.9 ± 0.7)	2.5 3 3.4 (2.9 ± 0.6)	0.02
Admission Diagnosis				
Bronchiolitis	374 (31%)	129 (16%)	44 (16%)	<0.01
Bronchopneumonia	476 (39%)	410 (52%)	134 (50%)	<0.01
Pneumonia	225 (19%)	126 (16%)	43 (16%)	0.28
Suspected sepsis	150 (12%)	65 (8%)	33 (12%)	0.01
Pertussis-like cough	51 (4%)	16 (2%)	8 (3%)	0.03
Presenting symptoms				
Fever	595 (49%)	463 (59%)	142 (53%)	<0.01
Cough	1176 (97%)	685 (87%)	205 (76%)	<0.01
Shortness of breath	964 (80%)	545 (69%)	175 (65%)	<0.01
Runny nose/congestion	38 (3%)	17 (2%)	9 (3%)	0.38
Decrease appetite	234 (19%)	95 (12%)	47 (18%)	<0.01
Seizures/convulsions	8 (1%)	19 (2%)	9 (3%)	<0.01
Decrease activity ^d	45 (16%)	22 (12%)	18 (20%)	0.15
Diarrhea	58 (5%)	63 (8%)	17 (6%)	0.01
Vomiting	149 (12%)	97 (12%)	41 (15%)	0.39
Key examination findings				
Cyanosis	339 (28%)	150 (19%)	64 (24%)	<0.01
Wheezing	926 (77%)	614 (78%)	217 (81%)	0.26
Flaring	173 (14%)	73 (9%)	35 (13%)	0.08
Abnormal x-ray ^e	1076 (90%)	674 (89%)	222 (84%)	0.02
Outcomes				
O ₂ requirement ^f	478 (40%)	248 (32%)	100 (38%)	0.002
Days on oxygen ^g (25th, 50th, 75th, mean, standard deviation)	1 2 5 (3.6 ± 3.3)	1 2 4 (3.3 ± 3.1)	1 2 3 (2.9 ± 3.1)	0.042
Mechanical ventilations ^h	48 (4%)	31 (4%)	15 (6%)	0.46
ICU stay ^h	107 (9%)	63 (8%)	40 (15%)	0.003
Median length of stay in days ⁱ (25th, 50th, 75th, mean, standard deviation)	2 3 6 (4.1 ± 3.3)	1 3 6 (4.2 ± 4.7)	1 3 6 (4.1 ± 4.3)	0.05
Death ^h	7 (0.6%)	7 (0.9%)	7 (3%)	0.007
Vitamin D level (ng/mL) ^j	15.1	20.3	20.5	<0.01

^a 2262.^b 2245.^c 2261.^d 553.^e 2216.^f 2239.^g 825.^h 2238.ⁱ 2241.^j 1942.

reports typically fail to include information from the Middle East region due to lack of published data. Therefore, our study fills a knowledge gap of RSV burden in the Arab region.

Our estimates of hospitalized RSV incidence are consistent and even slightly higher than other estimates from developed and developing countries in which RT-PCR was used to calculate RSV-associated hospital rates. For instance, our estimated RSV-associated hospitalization rates in children <6 months (range, 21–25 per 1000) were higher than a population-based study of three US hospitals that reported RSV-associated hospitalization rates for children <6 months as averaging 17 per 1000 (range: 12.4–21.7) over a five-year period, in which 20% (564/2892) of the subjects were RSV-positive [44]. In a large population-based study

of ARI in Egypt, of the 4993 children <5 years of age in which a specimen was collected, 518 (11%) of the children were positive by RSV by RT-PCR, with the highest portion in the 1–11 months group (45%). They estimated RSV-associated hospitalized rates in children 1–11 months as 17.45 per 1000 [42]. Of note, they excluded children <1 month of age, which most likely underestimated the burden of RSV. Other studies that estimated population-based RSV-associated hospital rates used less sensitive methods of RSV detection or only included children with children with severe ARI [45–48], making comparisons challenging. Our study highlights the importance of active surveillance over longer study periods and the advantage of sensitive molecular RSV detection techniques to accurately estimate the true burden of RSV hospitalizations.

Table 4

Univariate and multivariable analysis of factors associated with oxygen use, ICU stay, and mechanical ventilation in RSV-positive children.

Univariate analysis				Multivariable analysis		
Oxygen Use N = 1382	Oxygen N = 566 (%)	No oxygen N = 816 (%)	p-Value	Adjusted OR (95% CI)	p-Value	95% CI
Gender, male	321 (57%)	501 (61%)	0.08	1.21	0.15	0.94–1.56
Underlying medical condition	44 (8%)	63 (8%)	0.97	1.54	0.09	0.93–2.53
Daycare	13 (2%)	14 (2%)	0.44	1.52	0.38	0.60–3.86
Breastfeeding	482 (85%)	708 (87%)	0.40	0.60	0.01	0.40–0.89
Smoke exposure	428 (76%)	631 (77%)	0.46	1.14	0.39	0.85–1.53
Vitamin D level (ng/mL) ^a (25th, 50th, 75th, mean, standard deviation)	2.9 10.7 23.6 (14.1 ± 12.4)	4.6 15.8 26 (16.6 ± 12.5)	<0.01	0.89	0.67	0.69–1.15
Gestational age (weeks) (25th, 50th, 75th, mean, standard deviation)	38 40 40 (38.5 ± 2.3)	38 40 40 (38.8 ± 2.2)	0.02	0.90	0.30	0.71–1.14
Median age, months [IQR]	2.3	4.8	<0.01	0.26	<0.01	0.18–0.40
RSV ct count	24.9	26.4	<0.01	0.72	<0.01	0.59–0.87
Birth Weight	3	3	0.77	1.12	0.37	0.88–1.42
Pneumonia	128 (23%)	96 (12%)	<0.01	1.46	0.06	0.98–2.18
Bronchopneumonia	126 (22%)	342 (42%)	<0.01	0.65	0.04	0.43–0.98
Bronchiolitis	151 (27%)	221 (27%)	0.87	0.64	0.03	0.43–0.98
Sepsis	128 (23%)	120 (15%)	<0.01	0.57	0.01	0.37–0.86

Univariate analysis				Multivariable analysis		
ICU Stay N = 1381	ICU Stay N = 126 (%)	No ICU Stay N = 1255 (%)	p-value	Adjusted OR (95% CI)	p-value	95% CI
Gender, male	67 (53%)	754 (60%)	0.13	1.31	0.22	0.85–2.01
Underlying medical condition	12 (10%)	94 (7%)	0.41	1.45	0.43	0.58–3.59
Daycare	0 (0%)	27 (2%)	0.10	NA	NA	NA
Breastfeeding	102 (81%)	1087 (87%)	0.08	0.55	0.08	0.28–1.07
Smoke exposure	93 (74%)	965 (77%)	0.44	1.01	0.98	0.61–1.67
Vitamin D level (ng/mL) ^b	9.7	14.5	0.13	0.85	0.73	0.53–1.36
Gestational age (weeks)	39	40	<0.01	0.76	0.06	0.50–1.15
Median age (months) [IQR]	1.5	3.7	<0.01	0.35	0.02	0.17–0.74
RSV ct count	25.6	25.6	0.28	1.06	0.09	0.76–1.48
Birth Weight	3	3	0.08	0.88	0.55	0.59–1.33
Pneumonia	45 (36%)	179 (14%)	<0.01	1.89	0.02	1.11–3.20
Bronchopneumonia	12 (10%)	456 (36%)	<0.01	0.38	0.03	0.16–0.90
Bronchiolitis	22 (17%)	350 (28%)	0.01	0.70	0.31	0.36–1.38
Sepsis	59 (47%)	189 (15%)	<0.01	1.81	0.04	1.02–3.21

Univariate analysis				Multivariable analysis		
Mechanical ventilation (MV) N = 1381	MV N = 52 (%)	No MV N = 1329 (%)	p-value	Adjusted OR(95% CI)	p-value	95% CI
Gender, male	29 (56%)	792 (60%)	0.58	1.09	0.78	0.61–1.95
Underlying medical condition	4 (8%)	102 (8%)	1	0.85	0.80	0.24–3.04
Daycare	2 (4%)	25 (2%)	0.32	3.09	0.15	0.66–14.52
Breastfeeding	45 (87%)	1144 (86%)	0.92	1.54	0.38	0.59–4.00
Smoke exposure	41 (79%)	1017 (77%)	0.7	0.72	0.37	0.35–1.49
Vitamin D level (ng/mL) ^b	20.5	13.9	0.19	1.94	0.06	1.06–3.57
Gestational age (weeks)	40	40	0.58	0.87	0.21	0.50–1.50
Median age, months [IQR]	2.5	3.6	0.02	0.29	0.03	0.11–0.77
RSV ct count	26.8	25.6	0.53	1.25	0.39	0.77–2.05
Birth Weight	3.05	3	0.76	1.52	0.14	0.87–2.67
Pneumonia	14 (27%)	210 (16%)	0.03	1.83	0.16	0.78–4.28
Bronchopneumonia	13 (25%)	455 (34%)	0.17	1.04	0.94	0.38–2.81
Bronchiolitis	14 (27%)	358 (27%)	1	0.96	0.92	0.39–2.35
Sepsis	11 (21%)	237 (18%)	0.54	0.65	0.34	0.27–1.57

^a 1180.^b 1179.

Not only are the hospitalization rates of RSV-positive children higher compared to RSV-negative, but the clinical characteristics are different and the severity of illness seems to be greater in these children [14,44,49,50]. Prematurity and underlying medical conditions (e.g., heart or lung disease) are well-recognized risk factors for severe RSV [51]. However, the majority of our RSV-positive children were less likely to have been born prematurely or have an underlying medical condition compared to RSV-negative, consistent with other studies [34,44]. In our cohort, RSV-positive children were more likely to be admitted with evidence of lower respiratory involvement (e.g., higher frequency of pneumonia, bronchiolitis and bronchopneumonia diagnoses and physical findings such as wheezing and retractions), present

with hypoxemia and cyanosis, and require supplemental oxygen compared to RSV-negative children. Taken together, these results suggest that RSV is more likely to cause severe infection compared to other viruses.

Previously described risk factors associated with RSV hospitalization or severe illness include male sex, young age, birth in the first half of the RSV season, day care attendance, lack of breast feeding, chronic medical conditions, smoke exposure, and household crowding or siblings [44,52–58]. Using oxygen use as one of the indicators for severity, our results are consistent with other reports finding a significant higher odds ratios for oxygen use in RSV-positive children with higher RSV viral load [59,60], lack of breast feeding [61], and younger age [44]. When also evaluating

Table 5
Multivariable analysis of Factors Associated with Length of Stay in RSV-Positive Children.

	Adjusted OR (95% CI)	p-Value	95% CI
Gender, male	1.01	0.95	0.82–1.24
Underlying medical condition	1.63	0.02	1.10–2.42
Daycare	1.57	0.24	0.73–3.34
Breastfeeding	0.66	0.01	0.48–0.91
Smoke exposure	0.99	0.94	0.78–1.25
Vitamin D level (ng/mL)	0.97	0.64	0.78–1.19
Gestational age (weeks)	0.92	0.04	0.76–1.11
Age@Enrollment	0.39	<0.01	0.28–0.55
RSV ct count	0.68	<0.01	0.58–0.80
Birth Weight	0.87	0.16	0.71–1.05
Pneumonia	1.77	<0.01	1.27–2.46
Bronchopneumonia	0.71	0.04	0.51–0.99
Bronchiolitis	0.57	<0.01	0.41–0.79
Sepsis	2.08	<0.01	1.47–2.95

for ICU stay, mechanical ventilation, and length of stay, underlying medical conditions [51] and the admission diagnoses of pneumonia and suspected sepsis were other risk factors identified. Environmental tobacco smoke exposure is a known risk factor for serious RSV disease [62]. However, nearly 3/4 of our children were exposed to smoke; this high exposure for the cohort may explain why smoke exposure was not identified as an independent risk factor. Low vitamin D levels and clinical rickets have been associated with pneumonia and severe ARI [63–66]. Low vitamin D levels were associated with supplemental oxygen use in our univariate model; however, in the multivariable model it was no longer significant. Therefore, further investigation and public health interventions to reduce modifiable risk factors such as vitamin D supplementation, smoking cessation programs, and encouraging breastfeeding are needed in our population.

Prevention of RSV disease in young children may ultimately be possible with active immunization or maternal immunization, although no licensed RSV vaccine is currently available [67,68]. The only preventive measure for RSV disease is palivizumab, an RSV monoclonal antibody, which reduces the risk of hospitalization caused by RSV in high-risk children [69]. Use of palivizumab is low in low and middle income countries due to the high cost of the drug. The vast majority of children hospitalized with RSV in our study were full term and previously healthy. Therefore, even if palivizumab were available widely in Jordan, only a few children would have been eligible and thus it would have little impact on overall RSV hospitalization rates. Other strategies to reduce RSV-associated hospitalization are needed, such as infant or maternal vaccination with future vaccines or antiviral therapies specific for RSV.

Our study is one of the largest prospective cohorts of Middle East children hospitalized for ARI. Moreover, each subject had molecular viral testing performed for 11 viruses and systematic data collection. However, our study does have some limitations. The administration of oxygen and other treatments was at the clinicians' discretion and we only collected oxygen saturations at admission, so data may not reflect truly serious disease. Nevertheless, RSV children were more likely to have lower saturation at admission compared to RSV-negative children, suggesting that RSV is associated with increased morbidity. We did not collect current steroid use, except for inhaled steroids, prior or during admission, which may have an effect on viral load and/or fever presentation. Chest radiograph findings were reported by clinicians and were not

confirmed by independent radiologists. Children who were classified as virus-negative may have had other viral infections that we did not measure. Bacterial cultures were recorded when ordered by clinicians, but their reliability was uncertain because many infants received antibiotics before admission (over 40%) and the microbiology laboratory is not open for 24 h, delaying the processing of many specimens and therefore, we are not able to comment reliably about viral-bacterial co-infections. However, a recent prospective US study found that the majority of LRTI in hospitalized young children were caused by viral pathogens rather than bacteria (45). Since our RSV samples are not genotyped, we are unable to comment on differences in severity between RSV A and RSV B.

In conclusion, our three years of rigorous hospital surveillance confirm that RSV is a major cause of illness in young hospitalized Jordanian children. RSV is associated with increased severity compared to other respiratory viruses. Children in the Middle East would benefit from an RSV vaccine if one were available. In the meantime, public health policies directed at encouraging breastfeeding could be immediate interventions. RSV-specific chemotherapies are also needed. Future research on judicious use of antibiotics and the role of viral-bacterial co-detection are needed.

Funding source

This work was supported by the UBS Optimus Foundation; National Institutes of Health and the CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

Acknowledgments

We thank our research recruiters: Hanan Amin, Amani Altaber, Hana'a Khalaf, Isra'a Kharbat, Darin Yasin, Shireen Issa, and Nurse Sabah Gharbali.

References

- [1] Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. *J Exp Med* 2002;196(6):859–65.
- [2] Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. *Lancet* 2010;375(9725):1545–55.
- [3] Al-Sonboli N, Al-Aghbari N, Al-Aryani A, Atef Z, Brabin B, Shenkin A, et al. Micronutrient concentrations in respiratory syncytial virus and human metapneumovirus in Yemeni children. *Ann Trop Paediatr* 2009;29(1):35–40.
- [4] Al-Sonboli N, Hart CA, Al-Aghbari N, Al-Ansi A, Ashoor O, Cuevas LE. Human metapneumovirus and respiratory syncytial virus disease in children, Yemen. *Emerg Infect Dis* 2006;12(9):1437–9.
- [5] Al-Sonboli N, Hart CA, Al-Aeryani A, Banajeh SM, Al-Aghbari N, Dove W, et al. Respiratory syncytial virus and human metapneumovirus in children with acute respiratory infections in Yemen. *Pediatr Infect Dis J* 2005;24(8):734–6.
- [6] Naghipour M, Hart CA, Dove W, Leatherbarrow AJ, Cuevas LE. Adenovirus infections within a family cohort in Iran. *Pediatr Pulmonol* 2009;44(8):749–53.
- [7] Naghipour M, Hart CA, Cuevas LE. Burden of acute respiratory infections in a family cohort in Iran. *Epidemiol Infect* 2007;135(8):1384–8.
- [8] Naghipour M, Cuevas LE, Bakhshinejad T, Dove W, Hart CA. Human bocavirus in Iranian children with acute respiratory infections. *J Med Virol* 2007;79(5):539–43.
- [9] Naghipour M, Cuevas LE, Bakhshinejad T, Mansour-Ghanaei F, Noursalehi S, Alavy A, et al. Contribution of viruses *Chlamydia* spp. and mycoplasma pneumoniae to acute respiratory infections in Iranian children. *J Trop Pediatr* 2007;53(3):179–84.
- [10] Kaplan NM, Dove W, Abd-Eldayem SA, Abu-Zeid AF, Shamoon HE, Hart CA. Molecular epidemiology and disease severity of respiratory syncytial virus in relation to other potential pathogens in children hospitalized with acute respiratory infection in Jordan. *J Med Virol* 2008;80(1):168–74.

- [11] Kaplan NM, Dove W, Abu-Zeid AF, Shamooh HE, Abd-Eldayem SA, Hart CA. Human bocavirus infection among children, Jordan. *Emerg Infect Dis* 2006;12(9):1418–20.
- [12] Kaplan NM, Dove W, Abu-Zeid AF, Shamooh HE, Abd-Eldayem SA, Hart CA. Evidence of human metapneumovirus infection in Jordanian children. *Saudi Med J* 2006;27(7):1081–3.
- [13] Shafik CF, Mohareb EW, Yassin AS, Amin MA, El Kholy A, El-Karaksy H, et al. Viral etiologies of lower respiratory tract infections among Egyptian children under five years of age. *BMC Infect Dis* 2012;12:350.
- [14] Khuri-Bulos N, Williams JV, Shehabi AA, Faouri S, Al Jundi E, Abushariah O, et al. Burden of respiratory syncytial virus in hospitalized infants and young children in Amman, Jordan. *Scand J Infect Dis* 2010;42(5):368–74.
- [15] Miller EK, Khuri-Bulos N, Williams JV, Shehabi AA, Faouri S, Al Jundi I, et al. Human rhinovirus C associated with wheezing in hospitalised children in the Middle East. *J Clin Virol* 2009;46(1):85–9.
- [16] Ali SA, Williams JV, Chen Q, Faori S, Shehabi A, Jundi EA, et al. Human metapneumovirus in hospitalized children in Amman, Jordan. *J Med Virol* 2010;82(6):1012–6.
- [17] [www.ammancity.gov.jo/en/guide/guide.asp?catid=8&name=Hospital] website accessed 8/27/2015.
- [18] Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2008;42(2):377–81.
- [19] Ali S, Williams J, Chen Q, Faori S, Shehabi A, Al Jundi E, et al. Human metapneumovirus in hospitalized children in Amman, Jordan. *J Med Virol* 2010;82(6):1012–6.
- [20] Ali SA, Gern JE, Hartert TV, Edwards KM, Griffin MR, Miller EK, et al. Real-world comparison of two molecular methods for detection of respiratory viruses. *Virology* 2011;8:1–7.
- [21] Khuri-Bulos N, Payne DC, Lu X, Erdman D, Wang L, Faouri S, et al. Middle East respiratory syndrome coronavirus not detected in children hospitalized with acute respiratory illness in Amman, Jordan, March 2010 to September 2012. *Clin Microbiol Infect* 2014;20(7):678–82.
- [22] Khuri-Bulos N, Williams JV, Shehabi AA, Faouri S, Al Jundi E, Abushariah O. Burden of respiratory syncytial virus in hospitalized infants and young children in Amman, Jordan. *Scand J Infect Dis* 2010;42(5):368–74.
- [23] Klemenc J, Asad Ali S, Johnson M, Tollefson SJ, Talbot HK, Hartert TV. Real-time reverse transcriptase PCR assay for improved detection of human metapneumovirus. *J Clin Virol* 2012;54(4):371–5.
- [24] Kodani M, Yang G, Conklin LM, Travis TC, Whitney CG, Anderson LJ, et al. Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. *J Clin Microbiol* 2011;49(6):2175–82.
- [25] Lu X, Holloway B, Dare RK, Kuypers J, Yagi S, Williams JV. Real-time reverse transcription-PCR assay for comprehensive detection of human rhinoviruses. *J Clin Microbiol* 2008;46(2):533–9.
- [26] Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, et al. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. *Vaccine* 2008;26(32):4057–61.
- [27] Talbot HK, Shepherd BE, Crowe Jr JE, Griffin MR, Edwards KM, Podsiad AB, et al. The pediatric burden of human coronaviruses evaluated for twenty years. *Pediatr Infect Dis J* 2009;28(8):682–7.
- [28] Khuri-Bulos N, Lang RD, Blevins M, Kudyba K, Lawrence L, Davidson M. Vitamin D deficiency among newborns in Amman, Jordan. *Glob J Health Sci* 2014;6(1):162–71.
- [29] Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. *Stat Sci* 1992;457–72.
- [30] Population Total, [http://data.worldbank.org/indicator/SP.POP.TOTL].
- [31] Brooks SP, Catchpole EA, Morgan BJT. Bayesian animal survival estimation. *Stat Sci* 2000;15(4):357–76, a Review Journal of the Institute of Mathematical Statistics. Review Journal of the Institute of Mathematical Statistics.
- [32] Patil A, Huard D, Fonnesbeck CJ. Bayesian stochastic modelling in python. *J Stat Softw* 2010;35(4):1–81.
- [33] Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB, editors. *Bayesian data analysis*. Boca Raton, FL: CRC Press; 2013.
- [34] Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. *Pediatrics* 2013;132(2):e341–8.
- [35] Albargish KA, Hasany HJ. Respiratory syncytial virus infection among young children with acute respiratory tract infection in Iraq. *East Mediterr Health J* 1999;5(5):941–8.
- [36] Zaraket H, Dbaibo G, Salam O, Saito R, Suzuki H. Influenza virus infections in Lebanese children in the 2007–2008 season. *Jpn J Infect Dis* 2009;62(2):137–8.
- [37] Bdour S. Respiratory syncytial virus subgroup A in hospitalized children in Zarqa, Jordan. *Ann Trop Paediatr* 2001;21(3):253–61.
- [38] Meqdam MM, Nasrallah G, Al-Shurman A. Detection of adenovirus infection in children in Jordan. *Ann Trop Paediatr* 2001;21(1):59–65.
- [39] Meqdam MM, Nasrallah GK. Enhanced detection of respiratory syncytial virus by shell vial in children hospitalised with respiratory illnesses in northern Jordan. *J Med Virol* 2000;62(4):518–23.
- [40] Meqdam MM, Rawashdeh MO, Masaadeh H, Shurman AA, Abuharfeil N. Respiratory syncytial virus infection in infants hospitalized with respiratory illness in northern Jordan. *J Trop Pediatr* 1998;44(2):92–5.
- [41] Al-Toum R, Bdour S, Ayyash H. Epidemiology and clinical characteristics of respiratory syncytial virus infections in Jordan. *J Trop Pediatr* 2006;52(4):282–7.
- [42] Rowlinson E, Dueger E, Taylor T, Mansour A, Van Beneden C, Abukela M, et al. Incidence and clinical features of respiratory syncytial virus infections in a population-based surveillance site in the Nile delta region. *J Infect Dis* 2013;208(Suppl 3):S189–96.
- [43] Khadadah M, Essa S, Behbehani N, Al-Nakib W. Respiratory syncytial virus and human rhinoviruses are the major causes of severe lower respiratory tract infections in Kuwait. *J Med Virol* 2010;82(8):1462–7.
- [44] Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. *N Engl J Med* 2009;360(6):588–98.
- [45] Nokes DJ, Ngama M, Bett A, Abwao J, Munywoki P, English M, et al. Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance. *Clin Infect Dis* 2009;49(9):1341–9.
- [46] Nokes DJ, Okiro EA, Ngama M, Ochola R, White LJ, Scott PD, et al. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya. *Clin Infect Dis* 2008;46(1):50–7.
- [47] Nasreen S, Luby SP, Brooks WA, Homaira N, Al Mamun A, Bhuiyan MU, et al. Population-based incidence of severe acute respiratory virus infections among children aged <5 years in rural Bangladesh, June–October 2010. *PLoS ONE* 2014;9(2):e89978.
- [48] Muller-Pebody B, Edmunds WJ, Zambon MC, Gay NJ, Crowcroft NS. Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995–March 1998. *Epidemiol Infect* 2002;129(1):99–106.
- [49] Haynes AK, Manangan AP, Iwane MK, Sturm-Ramirez K, Homaira N, Brooks WA, et al. Respiratory syncytial virus circulation in seven countries with Global Disease Detection Regional Centers. *J Infect Dis* 2013;208(Suppl 3):S246–54.
- [50] Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. *N Engl J Med* 2015;372(9):835–45.
- [51] From the American Academy of Pediatrics: Policy statements—Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. *Pediatrics* 2009;124(6):1694–1701.
- [52] Nielsen HE, Siersma V, Andersen S, Gahrn-Hansen B, Mordhorst CH, Norgaard-Pedersen B, et al. Respiratory syncytial virus infection—risk factors for hospital admission: a case-control study. *Acta Paediatr* 2003;92(11):1314–21.
- [53] Bradley JP, Bacharier LB, Bonfiglio J, Schechtman KB, Strunk R, Storch G, et al. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. *Pediatrics* 2005;115(1):e7–14.
- [54] Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. *J Pediatr* 2003;143(5 Suppl):S118–26.
- [55] Boyce TG, Mellen BG, Mitchel Jr EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. *J Pediatr* 2000;137(6):865–70.
- [56] Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. *Am J Epidemiol* 1991;133(11):1135–51.
- [57] Simoes EA, Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. *Pediatr Infect Dis J* 2003;22(Suppl 2):S13–8, discussion S18–S20.
- [58] Simoes EA. RSV disease in the pediatric population: epidemiology, seasonal variability, and long-term outcomes. *Manage Care* 2008;17(11 Suppl 12):3–6, discussion 18–19.
- [59] El Saleeby CM, Devincenzo JP. Respiratory syncytial virus load and disease severity in the community. *J Med Virol* 2011;83(5):904–5.
- [60] DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. *J Infect Dis* 2005;191(11):1861–8.
- [61] Downham MA, Scott R, Sims DG, Webb JK, Gardner PS. Breast-feeding protects against respiratory syncytial virus infections. *Br Med J* 1976;2(6030):274–6.
- [62] DiFranza JR, Masaquel A, Barrett AM, Colosia AD, Mahadevia PJ. Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children. *BMC Pediatr* 2012;12:81.
- [63] Wayse V, Yousafzai A, Mogale K, Filteau S. Association of subclinical vitamin D deficiency with severe acute lower respiratory infection in Indian children under 5 y. *Eur J Clin Nutr* 2004;58(4):563–7.
- [64] Karatekin G, Kaya A, Salihoglu O, Balci H, Nuhoglu A. Association of subclinical vitamin D deficiency in newborns with acute lower respiratory infection and their mothers. *Eur J Clin Nutr* 2007.
- [65] Banajeh SM. Nutritional rickets and vitamin D deficiency—association with the outcomes of childhood very severe pneumonia: a prospective cohort study. *Pediatr Pulmonol* 2009;44(12):1207–15, <http://dx.doi.org/10.1002/ppul.21121>.
- [66] Muhe L, Lulseged S, Mason KE, Simoes EA. Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. *Lancet* 1997;349(9068):1801–4.
- [67] Englund JA. Prevention strategies for respiratory syncytial virus: passive and active immunization. *J Pediatr* 1999;135(2 Pt. 2):38–44.
- [68] Kaaijk P, Luytjes W, Rots NY. Vaccination against RSV: is maternal vaccination a good alternative to other approaches? *Hum Vaccin Immunother* 2013;9(6):1263–7.
- [69] Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics* 2014;134(2):415–20.